Physicians continue to perform imaging on asymptomatic patients with early-stage breast cancer, despite ASCO 2012 recommendations against it.
Imaging for metastases of asymptomatic patients with early-stage breast cancer continues, despite ASCO 2012 recommendations to the contrary, according to a study published in Journal of Oncology Practice.
Canadian researchers sought to determine if one recommendation of five issued by ASCO in 2012, that of ceasing routine advanced costly imaging technologies for staging of early breast cancer, was followed in local practices.
They performed a retrospective review of staging imaging for distant metastases performed in 200 patients with primary operable (early-stage) breast cancer seen at a large Canadian academic cancer center. One hundred patient records were from 2011, before the recommendations were issued, and 100 after September 2012.
The results showed that 169 patients (84.5%) underwent at least one imaging test, with a mean of 3.6 tests per imaged patient. A total of 154 patients (77.0%) underwent imaging that did not follow the local guideline recommendations. The researchers found that the frequency of imaging did not change after ASCO published its recommendations. “Furthermore, imaging to clarify indeterminate initial imaging was required in 51 (30.2 percent) of 169 patients,” the authors wrote. “None of the confirmatory imaging results ultimately revealed metastatic disease.”
The researchers concluded that although the local imaging guidelines advised against imaging for distant metastases in early-stage breast cancer, there was no reduction of imaging use in this population. “Broader knowledge translation strategies beyond publication are needed if recommendations are to be implemented into routine clinical practice,” they wrote.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.